NATCOPHARM.NS Profit & Loss

NATCO Pharma Ltd.

Profit & Loss · 6 years on file (FY2020-21 to FY2025-26) · fetched 2026-08-23 23:38

Line item	FY2020-21	FY2021-22	FY2022-23	FY2023-24	FY2024-25	FY2025-26	Source (XBRL element)
Revenue from Operations	₹20.52 Bn	₹19.45 Bn	₹27.07 Bn	₹39.99 Bn	₹44.30 Bn	₹40.78 Bn	RevenueFromOperations
Gross Revenue (incl. inter-segment)	₹20.52 Bn	₹19.45 Bn	₹27.07 Bn	₹39.99 Bn	₹44.30 Bn	₹40.78 Bn	SegmentRevenueFromOperations
Other Income	₹1.04 Bn	₹0.99 Bn	₹1.05 Bn	₹1.28 Bn	₹3.54 Bn	₹2.98 Bn	OtherIncome
Total Income	₹21.56 Bn	₹20.44 Bn	₹28.12 Bn	₹41.27 Bn	₹47.84 Bn	₹43.76 Bn	Income
Cost of Materials Consumed	₹3.73 Bn	₹5.19 Bn	₹4.75 Bn	₹5.22 Bn	₹5.36 Bn	₹5.93 Bn	CostOfMaterialsConsumed
Purchases of Stock-in-Trade	₹1.87 Bn	₹0.58 Bn	₹1.76 Bn	₹1.51 Bn	₹1.66 Bn	₹2.03 Bn	PurchasesOfStockInTrade
Changes in Inventories	₹-0.48 Bn	₹-0.17 Bn	₹-0.24 Bn	₹0.43 Bn	₹-0.12 Bn	₹-1.06 Bn	ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade
Employee Benefit Expense	₹4.15 Bn	₹4.45 Bn	₹4.87 Bn	₹5.25 Bn	₹5.95 Bn	₹6.87 Bn	EmployeeBenefitExpense
Finance Costs	₹0.13 Bn	₹0.18 Bn	₹0.14 Bn	₹0.19 Bn	₹0.24 Bn	₹0.37 Bn	FinanceCosts
Depreciation and Amortisation	₹1.17 Bn	₹1.43 Bn	₹1.64 Bn	₹1.87 Bn	₹2.35 Bn	₹2.07 Bn	DepreciationDepletionAndAmortisationExpense
Other Expenses	₹5.20 Bn	₹6.76 Bn	₹6.58 Bn	₹10.06 Bn	₹9.49 Bn	₹12.64 Bn	OtherExpenses
Total Expenses	₹15.76 Bn	₹18.42 Bn	₹19.50 Bn	₹24.53 Bn	₹24.93 Bn	₹28.85 Bn	Expenses
Profit Before Exceptional Items and Tax	₹5.80 Bn	₹2.02 Bn	₹8.62 Bn	₹16.73 Bn	₹22.91 Bn	₹14.91 Bn	ProfitBeforeExceptionalItemsAndTax
Exceptional Items	₹0.00 Bn	₹0.00 Bn	₹0.00 Bn	₹0.00 Bn	₹0.00 Bn	₹0.00 Bn	ExceptionalItemsBeforeTax
Profit Before Tax	₹5.80 Bn	₹2.02 Bn	₹8.62 Bn	₹16.73 Bn	₹22.91 Bn	₹14.91 Bn	ProfitBeforeTax
Tax Expense	₹1.37 Bn	₹0.32 Bn	₹1.47 Bn	₹2.85 Bn	₹4.08 Bn	₹1.19 Bn	TaxExpense
Net Profit (incl. minority interest)	₹4.42 Bn	₹1.70 Bn	₹7.15 Bn	₹13.88 Bn	₹18.83 Bn	₹14.19 Bn	ProfitLossForPeriod
Net Profit (to shareholders)	₹4.41 Bn	₹1.70 Bn	₹7.15 Bn	₹13.88 Bn	₹18.85 Bn	₹14.19 Bn	ProfitOrLossAttributableToOwnersOfParent
Basic EPS	₹24.20	₹9.32	₹39.18	₹77.34	₹105.26	₹79.20	BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations
Diluted EPS	₹24.16	₹9.32	₹39.18	₹77.34	₹105.26	₹79.20	DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations

Every figure above is the exact value of the named XBRL element from NATCOPHARM.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).